Literature DB >> 26284286

Creating New Economic Incentives for Repurposing Generic Drugs for Unsolved Diseases Using Social Finance.

Bruce E Bloom1.   

Abstract

Repurposing research improves patient lives by taking drugs approved for one disease and clinically testing them to create a treatment for a different disease. Repurposing drugs that are generic, inexpensive, and widely available and that can be taken in their current dosage and formulation in the new indication provide a quick, affordable, and effective way to create "new" treatments. However, generic drug repurposing often provides no profit potential, and so there is no economic incentive for industry to pursue this, and philanthropy and government funds are often insufficient. One way to create new economic incentive for the repurposing of generic drugs is through social finance. This perspective describes how social finance can create a new economic incentive by using a social impact bond, or similar financial structure, to repay for-profit investors who fund the repurposing research from the proceeds of healthcare cost reductions generated when these affordable, effective, and widely available repurposed therapies improve healthcare outcomes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26284286     DOI: 10.1089/adt.2015.29015.beddrrr

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  3 in total

1.  Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research.

Authors:  Ciska Verbaanderd; Ilse Rooman; Isabelle Huys
Journal:  Trials       Date:  2021-05-04       Impact factor: 2.279

2.  α-Lipoic Acid Exerts Its Antiviral Effect against Viral Hemorrhagic Septicemia Virus (VHSV) by Promoting Upregulation of Antiviral Genes and Suppressing VHSV-Induced Oxidative Stress.

Authors:  Wanwan Zhang; Xiaoqi Chen; Fangzhao Yu; Fengquan Li; Wangdong Li; Meisheng Yi; Kuntong Jia
Journal:  Virol Sin       Date:  2021-09-12       Impact factor: 4.327

3.  Overcoming Obstacles to Drug Repositioning in Japan.

Authors:  Yuhei Nishimura; Masaaki Tagawa; Hideki Ito; Kazuhiro Tsuruma; Hideaki Hara
Journal:  Front Pharmacol       Date:  2017-10-11       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.